Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure VI: Adjunct Therapies

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Heart Failure IV: Classification and Diagnostic Evaluation

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Analysis of application and match rates for clinical cardiac electrophysiology training in the United States.

Heart rhythm O2·2025

Same author

Increasing Rate of Unfilled Training Positions in the Advanced Heart Failure and Transplant Cardiology Match.

The American journal of cardiology·2025

Same author

Management of Patients With Impella 5.5 Left Ventricular Assist Devices on a Cardiovascular Stepdown Unit.

JACC. Heart failure·2025

Same author

Big tau aggregation disrupts microtubule tyrosination and causes myocardial diastolic dysfunction: from discovery to therapy.

European heart journal·2023

Same author

Does an Apple a Day Keep the Heart Failure Doctor Away?

JACC. Heart failure·2022

Same author

Role of Pulmonary Artery Wedge Pressure Saturation During Right Heart Catheterization: A Prospective Study.

Circulation. Heart failure·2020

Same journal

Biologic modulation of ineffective erythropoiesis in thalassemia: mechanisms, clinical practice, and future targets.

Expert opinion on biological therapy·2026

Same journal

TNF inhibitors for the long-term management of juvenile idiopathic arthritis associated uveitis: real-life data from the ITHACA cohort.

Expert opinion on biological therapy·2026

Same journal

Type 2 inflammation and biologics: a twenty-year journey.

Expert opinion on biological therapy·2026

Same journal

Current outlook on the use of biological agents to improve outcomes in adult secondary hemophagocytic lymphohistiocytosis.

Expert opinion on biological therapy·2026

Same journal

Addressing challenges in disease management of childhood-onset systemic lupus erythematosus: the role of biologics, with primary focus on rituximab and belimumab.

Expert opinion on biological therapy·2026

Same journal

Biological drugs for the treatment of children with atopic dermatitis.

Expert opinion on biological therapy·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Apr 6, 2026

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

Evolving targeted therapies for right ventricular failure.

Thomas G Di Salvo¹

¹Vanderbilt University Medical Center and School of Medicine, Vanderbilt Heat and Vascular Institute , Nashville, TN , USA +1 615 294 5437 ; +1 615 343 4841 ; Thomas.g.disalvo@vanderbilt.edu.

Expert Opinion on Biological Therapy

|August 4, 2015

Summary

This summary is machine-generated.

Exploring novel therapies for right ventricular failure, this review highlights emerging pharmacologic agents and future regenerative strategies. These approaches aim to address the unique challenges of right ventricular regeneration, offering new hope for patients.

Keywords:

epigenetic modulation myocardial regeneration right ventricular failure targeted therapies

More Related Videos

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice

Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice

Published on: May 13, 2019

Related Experiment Videos

Last Updated: Apr 6, 2026

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice

Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice

Published on: May 13, 2019

Area of Science:

Cardiovascular Research
Regenerative Medicine
Molecular Cardiology

Background:

Right and left ventricles exhibit distinct embryological origins, morphology, and cardiodynamics.
The concept of targeted therapies specifically for the right ventricle remains a subject of debate.

Purpose of the Study:

To review current and future therapeutic strategies for right ventricular failure.
To explore regenerative approaches for the right ventricle.

Main Methods:

Focuses on evolving pharmacologic agents for right ventricular failure.
Examines future therapeutic avenues including epigenetic modulation, gene therapy, cell regeneration, and cardiac tissue engineering.

Main Results:

Current pharmacologic agents include metabolic modulators and phosphodiesterase type V inhibitors.
Future strategies involve epigenetic modulation (miRNAs, lncRNAs), genomic editing, cell-based regeneration, and tissue engineering.

Conclusions:

Right ventricular regeneration necessitates a holistic approach distinct from left ventricular failure strategies.
Promising methods include in vivo fibroblast reprogramming into cardiomyocytes and targeted gene editing for genetic myocardial diseases.